Case Report

Rabson Mendenhall Syndrome; a Case Report and Review of Literature

Daniel Zamanfa¹, *, Fatemeh Mohamadi², Somayeh Rostami Maskopaii¹

¹Diabetes Research Center, Mazandaran University of Medical Sciences, Sari, Iran
²Research Department of Mazandaran University of Medical Sciences, Sari, Iran

Email address:
danielzamanfar@yahoo.com (D. Zamanfar), Mohamadi.f@yahoo.com (F. Mohamadi), Somayehrostami14@yahoo.com (S. R. Maskopaii)
*Corresponding author

To cite this article:
Daniel Zamanfa, Fatemeh Mohamadi, Somayeh Rostami Maskopaii. Rabson Mendenhall Syndrome; a Case Report and Review of Literature. International Journal of Environmental Chemistry. Vol. 4, No. 1, 2020, pp. 13-19. doi: 10.11648/j.ijec.20200401.12

Received: August 3, 2019; Accepted: January 8, 2020; Published: January 16, 2020

Abstract: Genetic disease is caused by a gene change. Genetic disease is one of the types of diseases affecting the personal, family and social life. One of the types of genetic disease is Rabson Mendenhall Syndrome. The Rabson Mendenhall Syndrome (RMS) was first described by Rabson and Mendenhall in 1956. Rabson Mendenhall syndrome is an extremely rare genetic disorder with autosomal recessive inheritance of unknown prevalence that is estimated to affect less than 1 per million people worldwide characterized by severe insulin resistance. The present study is a case report of a patient with Rabson Mendenhall Syndrome in Iran. A 6 year old girl presented with severe hyperglycemia and loss of consciousness and acidosis. In spite of taking large doses of insulin, her sugars were uncontrolled. She had severe acanthosis nigricans. There was associated growth retardation, dental dysplasia, distent abdomen, emaciated extremities and clitoromegaly. In last admission with diabetic ketoacidosis she was treated with intravenous fluids, insulin drip, metformin and also pioglitazone, antibiotics and other supportive treatments as needed, but unfortunately after few days this treatments could not save her and patient expired. There is no complete cure for the condition and the current treatments are difficult and not very promising.

Keywords: Diabetes Mellitus, Insulin Resistance, Rabson Mendenhall Syndrome

1. Introduction

The Rabson Mendenhall Syndrome (RMS) was first described by Rabson and Mendenhall in 1956. They described three siblings with insulin resistant diabetes mellitus having characteristic facial, skin, skeletal and dental features [1]. The other names of this condition are pineal hyperplasia and diabetes mellitus syndrome and also pineal hyperplasia, insulin resistant diabetes mellitus and somatic abnormalities. Rabson Mendenhall syndrome is an extremely rare genetic disorder with autosomal recessive inheritance of unknown prevalence that is estimated to affect less than 1 per million people worldwide characterized by severe insulin resistance. Homozygous mutations in Insulin receptor gene (INSR) are responsible for this syndrome [2]. The locus of mutation in INSR gene is 19 p 13.3- p 13.2 [3].

Mutations in the insulin receptor gene produce a spectrum of diseases including Donohue’s syndrome (leprechaunism), Rabson Mendenhall syndrome and type A insulin resistance; patients with these conditions have several different characteristics [4]. RMS in severity is between Donohue syndrome (fetal before second year of life) and type A insulin resistance (which is often not diagnosed before adolescence). Severe cases are diagnosed at birth or in infancy due to the presence of signs of severe hyperinsulinaemia such as acanthosis nigricans, abnormal dentition, hyperandrogenism and pseudo-acromegaly [5, 6].

The human insulin receptor is a heterotetramer composed of two extracellular alpha subunits that bind insulin and two beta subunits that span the plasma membrane and have an intracellular tyrosine kinase domain [4]. Mutations in the INSR gene cause inherited insulin-resistance syndromes (i.e. abnormal glucose homeostasis, acanthosis nigricans and ovarian hyperandrogenism (which range from mild to severe)
RMS is characterized by growth retardation, Failure to thrive, atrophy of muscles, coarse facies, widely spaced ayes, a broad nose and large low set ears, and skin manifestations such as hyperpigmentation, acanthosis nigricans and hypertrichosis. Dental abnormalities, enlarged phallus in males, clitoromegaly and multiple cysts on the ovaries in females, enlargement of nipples, genitalia, kidneys (nephromegaly), heart and other organs as penis in males, nephrocalcinosis, paradoxical fasting hypoglycemia, postprandial hyperglycemia, severe insulin resistance and hyperinsulinemia are other associated findings [7, 8].

2. Effective Mechanism of Insulin

Insulin receptors are heterotetrameric receptors consisting of two (α) and two (β) subunits. Insulin binds to the extracellular subunits of its receptor and activates the intracellular tyrosine kinase in the transmembrane subunits [3, 4]. Tyrosine kinase phosphorylates and recruits certain intracellular intermediates such as insulin-like substrates 1 and 2, Shc, and Gab1 [7]. These intermediate substances activate other signalling molecules like Growth factor receptor-bound protein 2, Cytoplasmic proteinNck, tyrosine phosphatase and the phosphoinositide-3 kinase, amplifying the initial effect generated by the insulin binding to its receptor. These complex interactions finally produce the expected insulin effects like uptake of glucose and amino acid by the cells, glycogenesis, fattyacid and cholesterol synthesis. In addition, insulin inhibits gluconeogenesis in the liver [4]. Any defects at any of the above mentioned steps of this complex pathway can lead to insulin resistance.

So in this patient the body may attempt to compensate for insulin resistance by increasing of insulin (hyperinsulinemia) but, with progression of disorder, insulin levels decrease and are no longer capable of suppressing glucose production and release by liver that resulting in constant hyperglycemia. Further decrease of insulin level compromise suppression of fatty acid oxidation and so constant ketoacidosis ensues [8].

3. A Genetic Factor

Although the molecular basis for extreme insulin resistance remains unknown in many patients, lipodystrophies and loss of function mutations in the insulin receptor gene are well established causes of this phenotype (Table 1) [9].

| No | INSR mutation |
|----|---------------|
| 1  | Pro193Leu Pro193Leu |
| 2  | Cys284Tyr Cys284Tyr |
| 3  | Ser323Leu Ser323Leu |
| 4  | Ile1116Thr Arg1131Trp |
| 5  | Pro970Thr Arg1131Trp |
| 6  | Arg1174Trp WT |
| 7  | Asn878Ser Ala1162Val |
| 8  | Cys159Phe Arg229Cys |
| 9  | Asn15Lys Arg1000X |
| 10 | Arg209His Gly359Ser |
| 11 | Arg86X Mu.p. Aas261 .Leu262insLeuHisLeuVal |
| 12 | IVS4-2A > G c. 2480-2487del |
| 13 | Ile321Phe |
| 14 | Ile348Phe c. 1042A > T |
| 15 | Pro220Leu |
| 16 | c. 5C > G, c. 123. G > T, c. 165. G > A |

4. Case Presentation

A 6 year old girl of Asian Iranian origin presented to us with poorly controlled diabetes. She didn’t use appropriate doses of insulin and she presented to us with DKA and her HbA1c was grossly elevated at 13.3%.

She was born as the first child of parents. Her younger brother are healthy. She was pre term (32 week) at birth and was delivered by lower segment cesarean section (LSCS) with a birth weight of 1500 gr (IUGR). She was developmentally normal. She had history of icter and cholestasis and hypothyroidy in infancy.

On examination she had growth retardation. Her height was 97 cm and she weighed 10 kg (both were below the 3 centile). She had severe acanthosis nigricans on the back of her neck and in the axillae. Her abdomen was protuberant and there was loss of subcutaneous fat on her buttocks and extremities, and mild clitoromegaly. Teeth showed dental dysplasia. Lipid profile was abnormal (TG 1900 mg/dl, chol 300 mg/dl, VLDL 38 mg/dl, LDL 52 mg/dl, HDL 49 mg/dl) and hemoglobin was (14.4 mmol/l). Chest X-ray and abdominal X-ray were normal. Her TSH was 2.4 mIU/l and free T4 was 1.4 mIU/l. Her sugar controlled with high dose insulin and metformin 500 mg twice a day and pioglitazone 15 mg three times per day.

Her sugars ranged between (200-500 mg/dl) with fasting of around (200-400mg/dl) and postparential (300-500 mg/dl).

In last admission with diabetic ketoacidosis she was treated with intravenous fluids, insulin drip, metformin and also pioglitazone, antibiotics and other supportive treatments as needed, but unfortunately after few days this treatments could not save her and patient expired.
5. Discussion

A number of syndromes are associated with insulin resistance like Type A and Type B insulin resistance syndromes, Leprechaunism, Lipodystrophy and Rabson Mendenhall syndrome (RMS), out of which type A insulin resistance syndrome, leprechaunism and RMS are caused by mutations in the insulin receptor gene. These syndromes can be suspected clinically but genetic studies to confirm the diagnosis should be done [3].
Rabson and Mendenhall in 1956 reported 3 siblings with dental and skin abnormalities, abdominal distension, phallic enlargement, early dentition, coarse senile faces, hirsutism, mental precocity, prognathism, thick fingernails and acanthosis nigricans [14]. The define of insulin resistance is a state of a tissue in which a greater than normal amount of insulin is required to elicit a quantitatively normal response [3]. Sever insulin resistance in an insulin-dependent subject might be suspected when requiring more than 200 units per day insulin [13].

But this definition does not reflect the possibility that the insulin resistance can be selective and only relate to particular functions of insulin. The more appropriate definition may be that insulin resistance exists whenever normal concentrations of insulin produce less than normal biological responses described by Kahn in 1976 with respect to glucose uptake, suppression of hepatic glucose production, decreased lipolysis, increased lipogenesis and prevention of proteolysis [13].

Our patient was noted to have all these features, except mental precocity. She also had growth retardation. This is because patients have intrauterine and postnatal growth restriction (due to defective mitogenic action of insulin). Children with RMS can develop diabetic ketoacidosis. These children have initially paradoxical fasting hypoglycemia due to the extremely elevated levels of circulating insulin at the time of fasting coupled with prolonged half-life of the hormone and postprandial hyperglycemia, but eventually develop constant hyperglycemia from a progressive decline of endogenous insulin level. Patients with Type A insulin resistance syndrome can be of either sex and typically have early onset of diabetes with severe inherited insulin resistance, acanthosis nigricans, hirsutism, in the absence of autoantibodies to the insulin receptor (IR) [15-17]. Type A insulin resistance syndrome and RMS have overlapping features but different clinical courses. Indeed this type is at the least sever end of the spectrum and may be also due to defect in post-receptor signaling [13]. Many of these patients paradoxically present with hypoglycemia. They have very elevated fasting insulin levels which may be sufficient to control fasting glucose levels but leads to post-prandial hypoglycemia due to mismatch between glucose and insulin [13]. This patients may have frank diabetes mellitus, virilization and polycystic vary syndrome [18]. The diagnosis encompasses in box sexes in teenage or early adulthood which are lean but have severe insulin resistance and acanthosis nigricans and also absence of insulin receptor autoantibodies [17]. These patients are likely to be at high risk of long term complications secondary to hyperglycemia but they are not predisposed to early mortality like other groups of insulin resistance [13].

Type B insulin resistance syndrome is an autoimmune condition with anti IR antibodies being the hallmark of this syndrome [15-17, 19]. These patients commonly present in middle age and show features of severe insulin resistance (acanthosis nigricans, abnormal glucose homeostasis etc) and autoimmunity (vitiligo, alopecia areata etc).

The lipodystrophy syndromes are a diverse group of disorders in differential diagnosis of RMS, characterised by severe insulin resistance and are associated with severe hypertriglycerideridemia and low HDL level [8, 15-17]. These syndromes have been sub classified according to the extent (partial or generalized), the location and the age of onset (congenital or acquired). Congenital lipodystrophy is characterized by extreme scarcity of fat in subcutaneous tissue, whereas acquired lipodystrophy is progressive and sometimes triggers with an infectious prodrome [15]. They characterized by abnormalities in adipose tissue, abnormalities of carbohydrate and lipid metabolism, sever insulin resistance and immune system dysfunction. Patient’s with RMS do not show raised triglycerid levels [8].

Leprechaunism presents with paradoxical fasting hypoglycemia, profound hyperinsulinemia and postprandial hyperglycemia. They have typical facial features like globular eyes, with flaring nostrils, low set ears and micrognathia. They have sever intrauterine growth retardation. Physical features typically include stunted growth and lipoatrophy. Few of these infants live beyond the first year of life, although a few may survive until adolescence. This finding have many similarities with RMS, but in RMS clinical symptoms are less severe than Donohue syndrome, and by the presence of more severe coarse feature, dysplastic dentition, gingival hyperplasia, pineal gland hyperplasia, ketoacidosis and survival beyond infancy [3, 17, 20].

Standard therapies in insulin resistance syndromes is generally supportive and the goal is maintenance of glucose in constant levels with frequent or continuous feeds and complex carbohydrates and insulin in not effective at usual doses and need to use extra-large doses of insulin (up to 9u/kg/h). Drug therapy for patients with severe insulin resistance syndromes is currently unsatisfactory. The combination of two insulin sensitizers (metformin and glitazone) is a well-known and validated therapy in patients with type 2 diabetes [17, 21, 22]. Patiens with RMS have been treated with high doses of insulin and insulin sensitizing drugs [4, 5, 10, 23]. The introduction of multi drug therapy especially in the early phase might improve glycemic control, allows the use of lower doses of insulin and delay microvascular complications [23]. A new approach for patients with RMS is the use of
dipeptidyl-peptidase-4 (DPP-4) inhibitors, which has been found to have some additional advantages when used as combination therapy. The use of DPP4 inhibitors alone has not been proved to be beneficial [21].

Recombinant methionyl human leptin (r-metHuLeptin) therapy has shown clear efficacy in the treatment of severe insulin resistance in patients with lipodystrophy and low leptin levels. Cochran et al., have shown a 40-60% decrease in fasting serum glucose and insulin levels and improved glycosylated hemoglobin in two siblings with RMS treated with r-metHuLeptin therapy for 10 months [23].

The mechanism is unclear [24-25]. One study showed that pharmacological doses of leptin in two RMS patients results in improvement of fasting hyperglycemia, hyperinsulinemia, glucose and insulin tolerance [12]. In rodent models several mechanisms could be relevant, include the activation of 5 AMP kinase which will increase insulin sensitivity also it is possible that there could be an effect on insulin receptor substrate-2 [26-27].

**Table 3. Summary design and outcome of studies on recombinant human insulin-like growth factor I (rhIGF-I) treatment in syndromes of severe insulin resistance [13].**

| Authors          | Trial design                                                                 | Outcome                                                                 |
|------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Schoenle et al.  | Three subjects twice received i.v. doses with rhIGF-1                         | Immediate slow fall in blood glucose, parallel fall in insulin and C-peptide levels |
| Morrow et al.    | Two subjects received 3-4 weeks treatment with rhIGF-I. Pre- and post-treatment assessment with 24 h glucose and insulin profile, standardised liquid meal, insulin tolerance test, insulin suppression test and i.v. glucose tolerance test | Decreased endogenous insulin levels, normalisation of response to i.v. insulin, reduced steady-state plasma glucose |
| Zenobi et al.    | Two subjects received 10 days treatment with rhIGF-I. Fasting and post-prandial glucose, insulin, C-peptide and proinsulin levels measured pre- and post-treatment | Fasting glucose levels decreased and fasting insulin, C-peptide, and proinsulin levels decreased by >65% during treatment |
| Kazuya et al.    | 11 subjects received up to 16 months treatment with rhIGF-I. Fasting and post-prandial glucose, fructosa-mine and %HbA1C were measured pre- and throughout treatment | Lowering of fasting and post-prandial glucose and decreases in fructosamine and %HbA1C |
| Moses et al.     | Six subjects (four out of six subjects had overt diabetes, two with normal glucose tolerance) received 1 months Treatment with rhIGF-I. Baseline investigation to quantify carbohydrate tolerance, insulin secretion and insulin action | Three out of four diabetic subjects showed normalization of fasting and post-prandial glucose levels. Remaining two subjects dramatically decreased insulin and triglyceride levels |
| Vestergaard et al. | Four subjects received high-dose treatment with rhIGF-I for 2 weeks, three subjects received low dose for 10 weeks. Pre- and post-treatment fasting glucose, insulin, C-peptide and proinsulin plus %HbA1C and fructosamine were measured | High-dose treatment lowered fasting glucose and insulin levels, whereas metabolic and glycaemic effects of 10 weeks low-dose treatment were modest |

In early studies very high doses of rhIGF1 were used and complications were observed like muscle pain, fluid retention, benign intracranial hypertension and worsening of retinopathy [16]. A study using rhIGF1 in a patient with Donohue’s syndrome reported normalization of glucose [43]. Recent studies have been able to explore the efficacy of IGF1 combined with IGF1BP3 in a variety of diabetic conditions [43-44]. This combination prolongs IGF1 half-life and result in decreased concentration of free IGF1 and improved tolerability [44-45].

An important results from there new studies was that complex therapy with IGF1/IGF1BP 3 would improve betacell function and glucose-stimulated c-peptide responses. Recent animal studies indicated that IGF1 signaling through the IGF1 receptor on the betacell may have an important role in maintaining betacell mass and insulin secretion [46-49].

This might indicate benefits of early rather than later treatment with rhIGF1 [13].

Recombinant leptin and / or IGF-1 might provide further therapeutic options for these patients in the event of secondary treatment failure [21].

With time these patients progress to persistent hyperglycaemia and diabetic ketoacidosis. This is due to progressive decline of insulin levels, which is inadequate to prevent glucose synthesis in the liver and prevent release of fatty acid by adipocytes [23].

RMS patients have a poor prognosis, but survival is higher than leprechaunism. Patients with leprechaunism generally die in the first two years of life and the survival in RMS is usually less than 20 years, although there are some documented cases with longer survival [24]. With the advent of newer therapies, the future holds promise for patients with RMS.
6. Conclusion

Thus, RMS is a rare genetic disorder, with characteristic morphological features. There is no complete cure for the condition and the current treatments are difficult and not very promising.

An important results from these new studies was that complex therapy with IGF1/IGF1BP3 would improve betacell function and glucose-stimulated c-peptide responses. Recent animal studies indicated that IGF1 signaling through the IGF1 receptor on the beta cell may have an important role in maintaining beta cell mass and insulin secretion [47-50]. This might indicate benefits of early rather than later treatment with rhIGF1 [13].

Therefore, careful research investigations to complete the therapeutic process are a necessity.

So early detection of the disease and controlling the symptoms of the disease is one of the priorities of supportive treatment in these patients. Providing health care to the patient and the support of companions and patient carers be a priority at the level of care because one of the most important health care in rare diseases is how to deal with the patient and choose the best treatment.

References

[1] Longo N, Langley SD, Griffin LD, Elyas LJ. Mutations in the insulin receptor and their effect on glucose transport. Trans. Assoc. Am Physicians. 1992; 105: 204-13.

[2] Sinnarajah K, Dayasiri M, Dissanayake N, Kudagammana S, Jayaweera A. Rabson Mendenhall Syndrome caused by a novel missense mutation. International journal of pediatric endocrinology. 2016; 2016 (1): 21.

[3] Ebina Y, Ellis L, Yamagin K, Edery M, Grafi L, Clauser E, et al. The human insulin receptor cDNA: the structural basis for the hormone-activated transmembrane signaling. Cell 1985; 40: 747-58.

[4] Taylor SI, Arioglu E. Genetically defined forms of diabetes in children. J Clin Endocrinol Metab. 1999; 84: 4390-6.

[5] Musso C, Chochean E, Moran SA, Skarulis MC, Oral EA, Taylor S, et al. Clinical course of genetic disease of insulin receptor (type A, and Rabson Mendenhall Syndrome). A 30 year prospective. Medicine 2004; 83: 209-22.

[6] Longo N, Wang Y, Pasquale M. Progressive decline in insulin levels in Rabson Mendenhall syndrome. J Clin Endocrinol Metab. 1999; 84: 2623-9.

[7] Hassan I, Altarf H, Yaseen A. Rabson-mendenhall syndrome. Indian journal of dermatology. 2014; 59 (6): 633.

[8] Garg A. Acquired and inherited lipodystrophies. New Engl J Medicine. 2004; 350: 1220-34.

[9] Ardon O, Procuer M, Tyrkik T, Longo N, Mao R. Sequencing analysis of insulin receptor defects and detection of two novel mutations in INSR gene. Molec Genet Metab Reports. 2014; 1: 71-84.

[10] Mohanan S, Chandrashekar L, Semple RK, Thappa DM, Parameswaran N, Negi VS, et al. Rabson-Mendenhall syndrome with recurrent cerebral infarcts caused by a novel INSR mutation. Int J Derm. 2013; 52 (182-5).

[11] Zaridoust A, Rabbani A, Sayarifard F, Thiel CT, Rezaei N. Acanthosis nigricans, abnormal facial appearance and dentition in an insulin resistance syndrome. Iranian journal of pediatrics. 2013; 23 (3): 363.

[12] McDonald A, Williams RM, Regan FM, Semple RK, Dunger DB. IGF-I treatment of insulin resistance. European Journal of Endocrinology. 2007; 157 (suppl_1): S51-S6.

[13] Bathi RJ, Parveen S, Mutalik S, Rao R. Rabson Mendenhall syndrome: two case reports and a brief review of the literature. Journal of Odontology. 2010; 98: 89-96.

[14] Tritos NA, Mantzoros CS. Clinical review 97: Syndromes of severe insulin resistance. J Clin Endocrinol Metab. 1998; 83: 3025-30.

[15] Vidal–Puig A, Moller DE. Insulin Resistance: classification, prevalence, clinical manifestations and diagnosis. In: Azziz R, Nestler JE. Androgen excess disorders in women. Philadelphia: Lippincott Raven. 1997: 227-36.

[16] Mantzoros CS, Filer JS. Insulin resistance: the clinical spectrum. In: Advances in Endocrine and metabolism. Mazzaferi E (ed). St. Louis Mosby-Year book. 1995; 6: 193-232.

[17] Kahn CR, Flier JS, Bar RS, Archer JA, Gordon P, Martin MM, et al. The syndromes of insulin resistance and acanthosis nigricans: insulin-receptor disorders in man. New England Journal of Medicine. 1976; 294 (14): 739-45.

[18] Alaei MR, Mirjavadi SA, Sharii R. Rabson-Mendenhall syndrome: A case report. Iranian Journal of Child Neurology. 2010; 4 (1): 49-52.

[19] Donohue WL, Uchida I. Leprechaunism: a euphemism for a rare familial disorder. J Pediatr 1954; 45: 32-6.

[20] Moreira RO, Zagury RL, Nascimento TS, Zagury L. Multidrug therapy in a patient with Rabson-Mendenhall syndrome. Diabetologia 2010; 53: 2454-5.

[21] Carrera P, Cordera R, Ferrari M, Cremonesi L, Taramelli R, Andraghetti G, et al. Substitution of Leu for Pro-193 in the insulin receptor in a patient with a genetic form of severe insulin resistance. Hum Mol Genet. 1993; 2: 1437-41.

[22] Chochran E, Young JR, Sebring N, DePaoli A, Oral EA, Gordon P. Efficacy of recombinant hu leptin therapy for the extreme insulin resistance of the RMS. J Clin Endo Metab. 2004; 89: 1548-54.

[23] Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, et al. Leptin-replacement therapy for lipodystrophy. New England Journal of Medicine. 2002; 346 (8): 570-8.

[24] Petersen KE, Oral EA, Dufour S, Belfroy D, Ariyan C, Yu C, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. The Journal of clinical investigation. 2002; 109 (10): 1345-50.

[25] Minokoshi Y, Kim Y-B, Peroni OD, Fryer LG, Müller C, Carling D, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 2002; 415 (6869): 339.

[26] Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Molecular cell. 2000; 6 (1): 77-86.
[27] Zapf J, Schoenle E, Froesch ER. Insulin-like growth factors I and II: some biological actions and receptor binding characteristics of two purified constituents of nonsuppressible insulin-like activity of human serum. European Journal of Biochemistry. 1978; 87 (2): 285-96.

[28] Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. Journal of Biological Chemistry. 1978; 253 (8): 2769-76.

[29] Ullrich A, Gray A, Tam AW, Yang - Feng T, Tsubokawa M, Collins C, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. The EMBO journal. 1986; 5 (10): 2503-12.

[30] Dimitriadis G, Parry-Billings M, Bevan S, Dunger D, Piva T, Krause U, et al. Effects of insulin-like growth factor I on the rates of glucose transport and utilization in rat skeletal muscle in vitro. Biochemical Journal. 1992; 285 (1): 269-74.

[31] Di Cola G, Cool MH, Accili D. Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors. The Journal of clinical investigation. 1997; 99 (10): 2534-44.

[32] Caro JF, Poulos J, Itttoop O, Pories WJ, Flickinger EG, Sinha MK. Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. The Journal of clinical investigation. 1988; 81 (4): 976-81.

[33] Acerini C, Harris D, Matyka K, Watts A, Umpleby A, Russell-Jones D, et al. Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus. Metabolism. 1998; 47 (12): 1481-9.

[34] Simpson HL, Jackson NC, Shojaee-Moradie F, Jones RH, Russell-Jones DL, Sööksen PH, et al. Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes. The Journal of Clinical Endocrinology & Metabolism. 2004; 89 (1): 425-32.

[35] Musso C, Shawker T, Cochran E, Javor ED, Young J, Gorden P. Clinical evidence that hyperinsulinaemia independent of gonadotropins stimulates ovarian growth. Clinical endocrinology. 2005; 63 (1): 73-8.

[36] Schoenle E, Zenobi P, Torresani T, Werder E, Zachmann M, Froesch E. Recombinant human insulin-like growth factor I (rhIGF-I) reduces hyperglycaemia in patients with extreme insulin resistance. Diabetologia. 1991; 34 (9): 675-9.

[37] Morrow LA, O'Brien M, Moller DE, Flier JS, Moses AC. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance. The Journal of Clinical Endocrinology & Metabolism. 1994; 79 (1): 205-10.

[38] Zenobi PD, Glatz Y, Keller A, Graf S, Jaeggi-Groisman SE, Riesien WF, et al. Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A. European journal of endocrinology. 1994; 131 (3): 251-7.

[39] Kuzuya H, Matsuura N, Sakamoto M, Makino H, Sakamoto Y, Kadowaki T, et al. Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes. 1993; 42 (5): 696-705.

[40] Moses AC, Morrow LA, O'Brien M, Moller DE, Flier JS. Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus. Diabetes research and clinical practice. 1995; 28: S185-S94.

[41] Vestergaard H, Rossen M, Urhammer SA, Müller J, Pedersen O. Short- and long-term metabolic effects of recombinant human IGF-I treatment in patients with severe insulin resistance and diabetes mellitus. European Journal of Endocrinology. 1997; 136 (5): 475-82.

[42] Nakae J, Kato M, Murashita M, Shinohara N, Tajima T, Fujieda K. Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism. The Journal of Clinical Endocrinology & Metabolism. 1998; 83 (2): 542-9.

[43] Cleemput DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J. The combination of insulin-like growth factor I and insulin-like growth factor-binging protein-3 reduces insulin requirements in insulin-dependent type I diabetes: evidence for in vivo biological activity. The Journal of Clinical Endocrinology & Metabolism. 2000; 85 (4): 1518-24.

[44] Boonen S, Rosen C, Bouillon R, Sommer A, McKay M, Rosen D, et al. Musculoskeletal effects of the recombinant human IGF-I/IGF binding-protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study. The Journal of Clinical Endocrinology & Metabolism. 2002; 87 (4): 1593-9.

[45] Bergerot I, Fabien N, Maguer V, Thivolet C. Insulin-like growth factor -1 (IGF -1) protects NOD mice from insulitis and diabetes. Clinical & Experimental Immunology. 1995; 102 (2): 335-40.

[46] Delevitch T. Insulin-like growth factors prevent cytokine-mediated cell death in isolated islets of Langerhans from pre-diabetic non-obese diabetic mice. Journal of Endocrinology. 1999; 161: 153-65.

[47] Chen W, Solojin KV, Mi Q-S, Grattan M, Meagher TC, Zucker P, et al. Insulin-like growth factor (IGF)-1/IGF-binding protein-3 complex: therapeutic efficacy and mechanism of protection against type I diabetes. Endocrinology. 2004; 145 (2): 627-38.

[48] Ueki K, Okada T, Hu J, Liew CW, Assmann A, Dahlgren GM, et al. Total insulin and IGF-I resistance in pancreatic β cells causes overt diabetes. Nature genetics. 2006; 38 (5): 583.